San Mateo, California, USA, September 3, 2026
Kali Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for KT501, enabling the company to advance U.S. clinical development of the investigational therapy. KT501 is described as a first-in-class CD19×BCMA×CD3 tri-specific T-cell engager (TCE) being developed for a broad range of B-cell-mediated autoimmune diseases. The regulatory milestone expands the clinical development pathway for the candidate beyond its ongoing first-in-human study in Australia. Kali said the IND clearance is supported by emerging safety, tolerability, pharmacokinetic and pharmacodynamic data from the Australian Phase 1a study in adults with rheumatoid arthritis. KT501 is being developed as an off-the-shelf biologic administered by subcutaneous injection, with a molecular design intended to achieve broad B-cell depletion while controlling cytokine-related toxicity.
Kali Advances KT501 Into U.S. Clinical Development
The FDA IND clearance represents an important regulatory milestone for KT501, allowing the investigational therapy to progress toward clinical evaluation in the United States. The ongoing first-in-human Phase 1a study (NCT07234773) is an open-label, dose-escalation trial evaluating a single subcutaneous dose of KT501 in adults with rheumatoid arthritis (RA). The study is designed primarily to assess safety and tolerability, while also characterizing the candidate’s pharmacokinetic and pharmacodynamic profiles. Kali is using the clinical program to evaluate whether its tri-specific approach can produce controlled and clinically meaningful depletion of disease-associated B-cell populations. The U.S. development program builds on the clinical experience generated in Australia and represents the next stage in the candidate’s broader development strategy. KT501 is designed to simultaneously recognize CD19, BCMA and CD3, bringing together three biological targets within a single antibody-based molecule. CD19 is expressed across many mature B-cell populations, while BCMA is expressed on plasma cells, including cells associated with antibody production. By engaging both CD19 and BCMA, Kali aims to reach a wider spectrum of B-cell populations than approaches directed against only one target. The third binding component, CD3, recruits T cells to the targeted cells and is intended to trigger their destruction. This multi-target strategy is being investigated as a potential means of achieving deeper B-cell depletion in autoimmune diseases.
KT501 Uses CD3 Masking to Control Cytokine Release
A key feature of KT501 is Kali’s proprietary CD3 masking design, which is intended to regulate T-cell engagement and potentially improve the therapeutic window of the molecule. T-cell engagers can generate powerful immune-cell activation, but excessive activation can lead to cytokine release and other safety concerns. Kali’s approach is designed to maintain potent target-cell depletion while limiting cytokine production. In non-human primate studies, the company reports that KT501 demonstrated potent B-cell depletion in peripheral blood and tissues together with significantly reduced cytokine production. These findings form part of the preclinical rationale supporting continued clinical development, although the ability of the masking strategy to separate potency from toxicity must ultimately be demonstrated in human studies. The candidate’s subcutaneous delivery is another important component of its development profile. Rather than requiring individualized manufacturing, KT501 is being developed as an off-the-shelf therapy, potentially providing a more scalable approach than personalized cellular therapies. The company believes the combination of broad B-cell targeting, controlled CD3 engagement and convenient administration could support development across multiple autoimmune indications. However, these potential advantages remain investigational, and the ongoing clinical program will be necessary to establish the safety, pharmacology and therapeutic activity of KT501 in patients.
Advertisement
Sanofi Partnership Supports KT501 Development
KT501 is also supported by a strategic relationship between Kali Therapeutics and Sanofi. In March 2026, the companies announced a worldwide exclusive license agreement under which Sanofi obtained rights to KT501. Under the agreement, Kali received upfront and near-term payments totaling $180 million and became eligible for up to $1.05 billion in development and commercial milestone payments, in addition to tiered royalties on product sales. The partnership reflects pharmaceutical-industry interest in next-generation approaches capable of producing targeted immune-system modulation for autoimmune diseases. The U.S. IND clearance now provides a regulatory foundation for expanding KT501’s clinical development. Kali intends to investigate the therapy across a broader range of B-cell-mediated autoimmune diseases, with rheumatoid arthritis serving as the initial clinical setting. The company’s strategy is based on the premise that simultaneous targeting of mature B cells and plasma cells could potentially provide deeper control of pathogenic immune activity. Nevertheless, KT501 remains investigational and is not FDA-approved. Future clinical data will be critical to determining whether the molecule’s preclinical properties translate into an acceptable benefit-risk profile and meaningful therapeutic effects for patients with autoimmune disease.
Source: Kali Therapeutics press release
